Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Health Services Research
Published in: BMC Health Services Research 1/2014

Open Access 01-12-2014 | Research article

Distribution and trends in outpatient utilization of generic versusbrand name psychopharmaceuticals during a ten-year period in Croatia

Authors: Marina Polić-Vižintin, Danijela Štimac, Zvonimir Šostar, Ingrid Tripković

Published in: BMC Health Services Research | Issue 1/2014

Login to get access

Abstract

Background

Drug costs increasingly pose a burden upon the otherwise inadequate health care resources and rational drug utilization is an important segment of every national health policy. Optimal patient care should be the goal of rational pharmacotherapy, whereby the economic burden of treatment is just one of the elements to be considered on choosing appropriate therapy.
The aim of this study was to determine distribution and trends in the outpatient utilization of generic versus brand name psychopharmaceuticals and to evaluate the rationality of prescribing psychopharmaceuticals during a ten-year period.

Methods

Using the World Health Organization Anatomical-Therapeutic-Chemical classification/Defined Daily Doses (ATC/DDD) methodology, the number of DDD was calculated from data collected from pharmacies on the number and size of drug packages. The ratio of generic and brand name drug costs served as an indicator on assessing the rationality of drug utilization.

Results

Total cost for psychopharmaceuticals increased by 20.1%, more for brand name than for generic agents (32.7% vs. 7.4%). The highest share of generic psychopharmaceuticals as compared with brand name drugs according to DDD per 1000 inhabitants per day (DDD/1000/day) was in the group of psycholeptics (83.6% in 2001 vs. 82.2% in 2010), most in hypnotics and sedatives, and least in antipsychotics. The share of generic psychopharmaceuticals in total drug utilization according to financial indicators decreased by 9.6% and according to DDD/1000/day by 12%. The greatest decrease was in antidepressants, i.e. by 33.8% according to financial indicators and by 46% according to DDD/1000/day; and in antipsychotics by 30.9% according to DDD/1000/day, while showing an increase by 8.5% according to financial indicators. In the therapeutic subgroup of mood stabilizers, the share of generic drugs in total drug utilization declined by 32% according to DDD/1000/day, but increased by 25.1% according to financial indicators.

Conclusions

The lack of uniform national guidelines and the still strong impact of pharmaceutical industry marketing continue favoring the rise in prescribing brand name antidepressants and antipsychotics. Depression, schizophrenia and bipolar diseases are complex diseases. As a result, specific measures are needed to encourage the prescribing of generic psychopharmaceuticals.
Literature
1.
Vukušić I, Čulig J: Izvori podataka o uporabi lijekova u Hrvatskoj i Europi. Acta Med Croatica. 2005, 59: 277-282.PubMed
2.
Štimac D, Vukušić I, Čulig J, Šostar Z, Bucalić M: Outpatient utilization of psychopharmaceuticals: comparison between Croatia and Scandinavian countries (2001-2003). Coll Antropol. 2009, 33: 237-43.PubMed
3.
4.
Godman B, Buscics A, Burkhardt T, Piessnegger J, Schmitzer M, Barbui C, Raschi E, Bennie M, Gustafsson L: Potential to enhance the prescribing of generic drugs in patients with mental health problems in Austria; implications for the future. Front Pharmacol. 2012, 3: 198.PubMed
5.
6.
Godman B, Shrank W, Andersen M, Berg CH, Bishop I, Burkhardt TH, Garuoliene K, Herholz H, Jopp R, Kalaba M, Laius O, Lonsdale J, Malmstrom RE, Martikainen JE, Samaluk V, Sermet C, Schwabe U, Teixeira I, Tilson L, Cankat Tulunay F, Vlahović-Palčevski V, Wendykowska K, Wettermark B, Zara C, Gustafsson LL: Policies to enhance prescribing efficiency in Europe: findings and future implications. Front Pharmacol. 2010, 1: 141.PubMed
7.
Bennie M, Godman B, Bishop I, Campbell S: Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res. 2012, 12: 125-130. 10.1586/erp.11.98.CrossRefPubMed
8.
Vogler S, Habl C, Bogut M, Vončina L: Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croat Med J. 2011, 52: 183-197. 10.3325/cmj.2011.52.183.CrossRefPubMedPubMedCentral
9.
Vončina L, Strizrep T, Godman B, Bennie M, Bishop I, Campbell S, Vlahović-Palčevski V, Gustafsson LL: Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2011, 11: 469-79. 10.1586/erp.11.42.CrossRefPubMed
10.
Croatian Institute of Health Insurance: Directive on the List of Drugs of the Croatian Institute of Health Insurance. Official Gazette. 2001, 65: 1-9. in Croatian
11.
Ministry of Health: Bylaw on the conditions and method of supplementary health insurance. Official Gazette. 2002, 28: 622-in Croatian
12.
Ministry of Health: Bylaw on the criteria for wholesale drug pricing and reporting. Official Gazette. 2004, 87: 1-3. in Croatian
13.
Ministry of Health: Bylaw on the criteria for wholesale drug pricing and reporting. Official Gazette. 2009, 155: 3-4. in Croatian
14.
Croatian Institute of Health Insurance: Directive on the essential list of drugs of the Croatian institute of health insurance. Official Gazette. 2006, 120: 8017-22. in Croatian
15.
Croatian Institute of Health Insurance: Directive on the supplementary list of drugs of the Croatian institute of health insurance. Official Gazette. 2006, 120: 8044-46. in Croatian
16.
Voncina L, Strizrep T: Croatia: 2009/2010 pharmaceutical pricing and reimbursement reform. Eurohealth. 2011, 16: 20-24.
17.
The EURO-MED-STAT Group: Monitoring expenditure and utilization of medicines in the European Union. A public health approach. Ital J Public Health. 2006, 3 (1): 15-21.
18.
19.
Croatian Institute of Health Insurance: Directive on the Essential List of Drugs of the Croatian Institute of Health Insurance. Official Gazette. 2010, 69: 102-28. in Croatian
20.
Croatian Institute of Health Insurance: Directive on the Supplementary List of Drugs of the Croatian Institute of Health Insurance. Official Gazette. 2010, 69: 147-56. in Croatian
21.
Borgheini G: The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther. 2003, 25 (6): 1578-1592. 10.1016/S0149-2918(03)80157-1.CrossRefPubMed
22.
Cuenca E, Zaragoza F: Generic drugs in psychopharmacology: pros and cons. Actas Esp Psiquiatr. 1999, 27 (6): 351-357.PubMed
23.
Wu EQ, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH: Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Ann Pharmacother. 2011, 45 (4): 441-451. 10.1345/aph.1P482.CrossRefPubMed
24.
Vlahiotis A, Devine ST, Eicholz J, Kautzner A: Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans. J Manag Care Pharm. 2011, 17 (2): 123-132.PubMed
25.
Liu X, Chen Y, Faries D: Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder. Clinicoecon Outcomes Res. 2011, 3: 63-72.PubMedPubMedCentral
26.
Godman B, Persson M, Miranda J, Skiold P, Wettermark B, Barbui C, Gustafsson LL: Change in utilization of venlafaxine after introduction of generics in Sweden. Appl Econ Health Policy. 2013, 11 (4): 383-393. 10.1007/s40258-013-0037-x.CrossRef
27.
Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, Brookhart MA, Avorn J, Shrank WH: Seizure outcomes following use of generic vs. brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs. 2010, 70: 605-621. 10.2165/10898530-000000000-00000.CrossRefPubMedPubMedCentral
28.
Buck TC, Schmedes A, Branslund I: Does generic lamotrigine lead to larger variations in plasma concentrations?. Ugeskr Laegr. 2007, 169 (21): 2013-2015.
29.
Hartung DM, Middleton L, Svoboda L, McGregor JC: Generic substitution of lamotrigine among Medicaid patients with diverse indications: a cohort-crossover study. CNS Drugs. 2012, 26 (8): 707-716. 10.2165/11634260-000000000-00000.CrossRefPubMedPubMedCentral
30.
Valenstein M, Ganoczy D, McCarthy JF, Myra KH, Lee TA, Blow FC: Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006, 67: 1542-1550. 10.4088/JCP.v67n1008.CrossRefPubMed
31.
Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004, 161: 692-699. 10.1176/appi.ajp.161.4.692.CrossRefPubMed
32.
Treur M, Heeg B, Moller HJ, Schmeding A, Van Hout B: A pharmaco-economic analysis with schizophrenia switching to generic risperidone involving a possible compliance loss. BMC Health Serv Res. 2009, 9: 32-10.1186/1472-6963-9-32.CrossRefPubMedPubMedCentral
33.
Ganther JM, Kreling DH: Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc (Wash). 2000, 40: 378-383.CrossRef
34.
Araszkiewitcz AA, Szabert K, Godman B, Wladysiuk M, Barbui C, Haycox A: Generic olanzapine: health authority opportunity or nightmare?. Expert Rev Pharmacoecon Outcomes Res. 2008, 8: 549-555. 10.1586/14737167.8.6.549.CrossRef
35.
Jakovljević M: Suvremena terapija shizofrenije od neurobiologije do potpune reintegracije. 2001, Zagreb: Medicinska naklada, Pro Mente
36.
Godman B, Bishop I, Finlayson AE, Campbell S, Kwon HY, Bennie M: Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res. 2013, 13: 469-482. 10.1586/14737167.2013.820956.CrossRefPubMed
37.
Wladysiuk M, Araszkiewicz A, Godman B, Szabert K, Barbui C, Haycox A: Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available. Appl Health Econ Health Policy. 2011, 9: 101-110. 10.2165/11318840-000000000-00000.CrossRefPubMed
38.
Garuoliene K, Godman B, Gulbinovic J, Wettermark B, Haycox A: European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011, 11: 343-349. 10.1586/erp.11.24.CrossRefPubMed
39.
40.
Bennie M, Bishop I, Godman B, Barbui C, Raschi E, Campbell S, Miranda J, Gustafsson LL: Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. Int J Clin Pract. 2013, 67: 170-180. 10.1111/ijcp.12100.CrossRefPubMed
41.
Godman B, De Bruyn K, Miranda J, Raschi E, Bennie M, Barbui C, Simoens S: Generic atypical antipsychotic drugs in Belgium: their influence and implications. J Comp Eff Res. 2013, 2: 551-561. 10.2217/cer.13.75.CrossRefPubMed
42.
Brkičić LS, Godman B, Vončina L, Sović S, Relja M: Initiatives to improve prescribing efficiency for drugs to treat Parkinson’s disease in Croatia:influence and future directions. Expert Rev Pharmacoecon Outcomes Res. 2012, 12: 373-384. 10.1586/erp.12.24.CrossRefPubMed
Metadata
Title
Distribution and trends in outpatient utilization of generic versusbrand name psychopharmaceuticals during a ten-year period in Croatia
Authors
Marina Polić-Vižintin
Danijela Štimac
Zvonimir Šostar
Ingrid Tripković
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2014
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/1472-6963-14-343

Other articles of this Issue 1/2014

BMC Health Services Research 1/2014 Go to the issue

Research article

A national survey of inpatient medication systems in English NHS hospitals

Research article

Scheduled telephone visits in the veterans health administration patient-centered medical home

Research article

High-cost health care users in Ontario, Canada: demographic, socio-economic, and health status characteristics

Research article

Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool

Research article

Costs associated with febrile neutropenia in solid tumor and lymphoma patients – an observational study in Singapore

Research article

International prevalence of adverse drug events in hospitals: an analysis of routine data from England, Germany, and the USA